A Feasibility Study on Ultrafiltration and Blood Volume Measurements
Sponsor: Daxor Corporation
Terminated
Slow enrollment
Other terminated trials from Daxor Corporation
More terminations from Daxor Corporation
Other Acute Decompensated Heart Failure trials with similar outcome
This NA trial investigates Acute Decompensated Heart Failure and Fluid Overload and is currently terminated or withdrawn. Daxor Corporation leads this study, which shows 10 recorded versions since 2019 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
10 versions recorded-
Dec 2024 — Present [monthly]
Terminated NA
-
Sep 2024 — Dec 2024 [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Mar 2023 — Jul 2024 [monthly]
Terminated NA
Status: Recruiting → Terminated
-
Sep 2022 — Mar 2023 [monthly]
Recruiting NA
▶ Show 5 earlier versions
-
Jun 2022 — Sep 2022 [monthly]
Recruiting NA
-
Oct 2021 — Jun 2022 [monthly]
Recruiting NA
-
Feb 2021 — Oct 2021 [monthly]
Recruiting NA
-
Jan 2021 — Feb 2021 [monthly]
Recruiting NA
-
Feb 2020 — Jan 2021 [monthly]
Recruiting NA
First recorded
Dec 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Daxor Corporation
- Nuwellis, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .